Understanding how DNA repair issues affect ovarian cancer treatment outcomes
Dissecting the interaction between DNA damage repair defects and the tumor microenvironment
This study is looking at how problems with DNA repair in ovarian cancer cells affect how well the cancer responds to chemotherapy, especially carboplatin, and aims to find ways to improve treatment for patients facing this challenge.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10913470 on NIH RePORTER |
What this research studies
This research investigates the relationship between defects in DNA damage repair mechanisms and the tumor microenvironment in high grade serous ovarian cancer. By analyzing patient-derived organoids, the study aims to understand how these defects influence the tumor's response to chemotherapy, particularly carboplatin. The research will explore how initial sensitivity to treatment can change to resistance due to alterations in the tumor's cellular interactions and environment after chemotherapy. This could provide insights into improving treatment strategies for patients with ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high grade serous ovarian cancer who have undergone or are undergoing neoadjuvant chemotherapy.
Not a fit: Patients with other types of ovarian cancer or those who have not received chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for ovarian cancer patients, particularly those with DNA repair defects.
How similar studies have performed: Previous research has shown promising results in understanding DNA repair mechanisms in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Hill, Sarah James — Dana-Farber Cancer Inst
- Study coordinator: Hill, Sarah James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.